{"filing":{"accession_number":"0001104659-26-077470","cik":"0001574232","ticker":"ADXN","company_name":"Addex Therapeutics Ltd.","form":"6-K","filing_date":"2026-06-25","report_date":null,"primary_document":"tm2618934d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926077470/tm2618934d1_6k.htm"},"events":[{"id":13656,"run_id":12124,"accession_number":"0001104659-26-077470","anchor_item_number":"EX-99.3","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a press release disclosing Q1 2026 financial results for Addex Therapeutics, including income, R\u0026D expenses, G\u0026A expenses, operating loss, net loss, loss per share, cash position, and shareholders' equity. The document explicitly states \"Addex Therapeutics Reports First Quarter 2026 Financial Results\" and provides a detailed financial summary table with comparative Q1 2025 data. This is a discrete earnings announcement, not a periodic financial report filing itself.","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-06-25","form":"6-K","submitted_at":null,"items":[{"id":10862,"accession_number":"0001104659-26-077470","item_number":"EX-99.3","item_title":"tm2618934d1_ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing Q1 2026 financial results for Addex Therapeutics, including income, R\u0026D expenses, G\u0026A expenses, operating loss, net loss, loss per share, cash position, and shareholders' equity. The document explicitly states \"Addex Therapeutics Reports First Quarter 2026 Financial Results\" and provides a detailed financial summary table with comparative Q1 2025 data. This is a discrete earnings announcement, not a periodic financial report filing itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:05:10.132065+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10860,"accession_number":"0001104659-26-077470","item_number":"EX-99.1","item_title":"tm2618934d1_ex99-1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is an unaudited interim condensed consolidated financial report for the three-month period ended March 31, 2026, comprising balance sheets, statements of comprehensive loss, changes in equity, and cash flows. The document explicitly states it is prepared under IAS 34 \"Interim Financial Reporting\" and represents interim financial statements, not a discrete earnings release or event. The going-concern disclosure in Note 3 is material but is part of the periodic financial report itself, not a separate event triggering a different classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:05:10.132065+00:00","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-06-25"},{"id":10861,"accession_number":"0001104659-26-077470","item_number":"EX-99.2","item_title":"tm2618934d1_ex99-2.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a Management's Discussion and Analysis (MD\u0026A) of Financial Condition and Results of Operations covering the three-month period ended March 31, 2026. It is part of an interim financial report (unaudited interim condensed consolidated financial statements as referenced in the text), not a discrete event disclosure. The document discusses historical revenue, operating expenses, and financial position as of March 31, 2026, and is clearly a periodic interim financial report rather than an earnings release or material event announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:05:10.132065+00:00","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-06-25"},{"id":10862,"accession_number":"0001104659-26-077470","item_number":"EX-99.3","item_title":"tm2618934d1_ex99-3.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a press release disclosing Q1 2026 financial results for Addex Therapeutics, including income, R\u0026D expenses, G\u0026A expenses, operating loss, net loss, loss per share, cash position, and shareholders' equity. The document explicitly states \"Addex Therapeutics Reports First Quarter 2026 Financial Results\" and provides a detailed financial summary table with comparative Q1 2025 data. This is a discrete earnings announcement, not a periodic financial report filing itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-25T10:05:10.132065+00:00","company_name":"Addex Therapeutics Ltd.","ticker":"ADXN","filing_date":"2026-06-25"}]}